argenx to Host Q3 2024 Financial Results Conference Call
On October 31, 2024, argenx, a global leader in immunology dedicated to improving the lives of individuals with severe autoimmune diseases, plans to announce its financial results for the third quarter of 2024. The company will also provide updates on its ongoing business initiatives.
Details of the Upcoming Call
The conference call is set to begin at 1:30 PM CET (8:30 AM ET) and will be accessible through a live audio webcast on the Investors section of the argenx website. Participants are encouraged to log in early, as it will offer insights into the company's performance and future prospects.
Joining the Conference Call
For those wishing to join the call, the following dial-in numbers are available for various regions:
- Belgium: 32 800 50 201
- France: 33 800 943355
- Netherlands: 31 20 795 1090
- United Kingdom: 44 800 358 0970
- United States: 1 888 415 4250
- Japan: 81 3 4578 9081
- Switzerland: 41 43 210 11 32
When dialing in, participants should use the access code 3810049 and aim to connect approximately 15 minutes prior to the start of the call.
About argenx
Argentx has positioned itself at the forefront of immunology. With a commitment to enhancing the quality of life for patients with serious autoimmune conditions, argenx collaborates with prominent academic researchers under its Immunology Innovation Program. This initiative aims to translate groundbreaking immunological research into an impressive portfolio of innovative antibody-based therapies.
Key Developments in Their Portfolio
Among its notable achievements, argenx has developed the first approved neonatal Fc receptor (FcRn) blocker, which is currently being commercialized across multiple global markets, including countries such as the U.S., EU, Japan, and Canada. Additionally, the company is actively assessing efgartigimod in various serious autoimmune diseases and advancing several experimental therapies within its therapeutic areas.
Future Directions and Research Focus
Argentx is not only committed to ongoing innovation but is also strategically expanding its research into new areas of autoimmune diseases. This focus reflects the company's dedication to tackling unmet medical needs and solidifying its reputation as a leader in immunological therapies.
Frequently Asked Questions
What is the date and time of the conference call?
The conference call will take place on October 31, 2024, at 1:30 PM CET (8:30 AM ET).
How can I access the live audio webcast?
The live audio webcast can be accessed through the Investors section on the argenx website.
Which countries can dial in to the conference call?
Participants from Belgium, France, the Netherlands, the United Kingdom, the United States, Japan, and Switzerland can dial in using the provided numbers.
What is the access code for the call?
Participants should use the access code 3810049 to join the call.
What does argenx specialize in?
Argentx is a global immunology company focused on developing innovative therapies for severe autoimmune diseases.